Browse Jobs
Browse fresh roles from company career pages, then filter by keyword, location, salary, skills, remote scope, and more. Each listing links back to the employer-controlled apply path when available.
Browse fresh roles from company career pages, then filter by keyword, location, salary, skills, remote scope, and more. Each listing links back to the employer-controlled apply path when available.
Invert
What we're building Drug development is one of the most data-intensive endeavors in history, yet scientists spend more time finding and cleaning data than using it. Bioprocess data is high-frequency, multi-source, and scattered across systems that rarely talk to each other. We m
Invert
What we're building Drug development is one of the most data-intensive endeavors in history, yet scientists spend more time finding and cleaning data than using it. Bioprocess data is high-frequency, multi-source, and scattered across systems that rarely talk to each other. We m
Invert
What We're Building Drug development is one of the most data-intensive endeavors in human history. Yet scientists spend more time finding and cleaning data than actually using it, slowing down drugs that should reach patients faster and more affordably. Biopharma has seen billio
Invert
What We're Building Drug development is one of the most data-intensive endeavors in human history. Yet scientists spend more time finding and cleaning data than actually using it, slowing down drugs that should reach patients faster and more affordably. Biopharma has seen billio
Invert
What We're Building Drug development is one of the most data-intensive endeavors in human history. Yet scientists spend more time finding and cleaning data than actually using it, slowing down drugs that should reach patients faster and more affordably. Biopharma has seen billio
Invert
What We're Building Drug development is one of the most data-intensive endeavors in human history. Yet scientists spend more time finding and cleaning data than actually using it, slowing down drugs that should reach patients faster and more affordably. Biopharma has seen billio